Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05415358 · ClinicalTrials.gov registry record
Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients
A clinical trial of Lung Cancer, Nonsmall Cell, sponsored by Wake Forest University Health Sciences.
- Active
- Registry status
- 23
- Enrollment target
- 2
- Study locations
NCT05415358 is a study of Lung Cancer, Nonsmall Cell that is active but no longer recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 23 participants, below the 790-participant average among 5 other Lung Cancer, Nonsmall Cell trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05415358, a study of Lung Cancer, Nonsmall Cell, is active but no longer recruiting, sponsored by Wake Forest University Health Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- 23 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combination chemotherapy for mNSCLC.
Conditions Studied
Interventions
- OTHER Blood and tissue samples
Study Locations (2)
North Carolina
- Atrium Health Levine Cancer - Charlotte
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2035-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05415358
The ClinicalTrials.gov registry entry for NCT05415358 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 790-participant average among 5 other Lung Cancer, Nonsmall Cell trials with a reported enrollment target (97% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer, Nonsmall Cell appearing as the primary indexed condition, and to 1 intervention - of which Blood and tissue samples is the first listed.
NCT05415358 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05415358 about?
NCT05415358 is a clinical study titled "Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients". The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combinat...
What is the current status of trial NCT05415358?
This trial is currently active not recruiting. The enrollment target is 23 participants. The study started on 2023-01-17. Estimated completion is 2035-09.
What conditions does trial NCT05415358 study?
This clinical trial studies the following conditions: Lung Cancer, Nonsmall Cell.
What interventions are being tested in trial NCT05415358?
The interventions under investigation include: Blood and tissue samples (OTHER).
Who is sponsoring clinical trial NCT05415358?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05415358 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer, Nonsmall Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
RECRUITING
-
A Multicenter Cancer Biospecimen Collection Study
RECRUITING
-
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
RECRUITING · Phase 1
-
Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.